Rubius Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue
Operating expenses:
Research and development
General and administrative
Restructuring and impairment charges
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Interest income and other income (expense), net
Change in fair value of preferred stock warrant liability
Other income, net
Total other income (expense), net

Net loss
Other comprehensive income (loss):
Unrealized losses on investments, net of tax of $0
Comprehensive loss
Net loss per share, diluted (in dollars per share)
Net loss per share, basic (in dollars per share)
Weighted average number of shares outstanding, diluted (in shares)
Weighted average number of shares outstanding, basic (in shares)

Comments